Latest Insights - page 51 | BiopharmaTrend

Evogene Partners with Google Cloud to Build AI Model for Small Molecule Discovery

Computational biology firm Evogene Ltd. has partnered with Google Cloud to develop an advanced AI foundation model for small molecule design, building on the recent integration of Evogene’s ChemPass AI …

Continue ›››

Absci and Twist Bioscience Collaborate to Design a Novel Antibody with Generative AI

Absci Corporation and Twist Bioscience have announced a collaboration to create a novel therapeutic antibody, integrating Absci’s generative AI drug design platform with Twist’s silicon-based DNA synthesis technology. This partnership …

Continue ›››

Novo Nordisk Foundation Launches Denmark’s First AI Supercomputer to Accelerate Drug Discovery and Innovation

In a major step for Danish research and industry, the Novo Nordisk Foundation has introduced "Gefion," Denmark's first AI supercomputer, supported by an initial investment of DKK 600 million (approximately …

Continue ›››

Quris-AI Acquires Nortis to Enhance Drug Safety with Kidney-on-Chip Tech

Quris-AI, a company dedicated to enhancing drug safety prediction, has announced its acquisition of Kidney-on-Chip pioneer Nortis, also known as Numa Biosciences, Inc. The addition of Nortis’s microphysiology systems (MPS) …

Continue ›››

Medable Launches Clinical Trial Platform on Google Cloud Marketplace, Expands AI Integration

Medable Inc. has launched its Digital and Decentralized Clinical Trial Platform on Google Cloud Marketplace, bringing advanced trial management and design tools directly to life sciences organizations through Google’s cloud …

Continue ›››

Archon Biosciences Raises $20M to Develop AI-Enhanced "Antibody Cages" for New Therapeutics

Seattle’s Archon Biosciences, co-founded by David Baker, a recent Nobel Prize winner, has raised $20 million in seed funding to advance “antibody cages” — a new approach that adds AI-designed …

Continue ›››

Gene Therapy: Lexeo Therapeutics’ LX1001 Shows Promise for APOE4-Associated Alzheimer’s Disease

Lexeo Therapeutics recently presented interim findings from its ongoing Phase 1/2 trial of LX1001, a gene therapy targeting Alzheimer’s disease in patients with two copies of the APOE4 allele, at …

Continue ›››

Ataraxis AI Steps Forward in Precision Cancer Care With $4 Million in Seed Funding

Today, Ataraxis AI emerged from stealth with $4 million in seed funding to develop AI-driven cancer diagnostics aimed at advancing precision medicine. Co-founded by Jan Witowski, MD, PhD, and AI …

Continue ›››

Insilico Medicine and Sanofi Report AI-Enabled Milestone in Drug Discovery for Oncology

Insilico Medicine, a biotechnology company focused on AI-driven drug discovery, announced a milestone in its collaboration with Sanofi, targeting “undruggable” molecular sites within oncology. Established in November 2022, the collaboration …

Continue ›››

Iambic Therapeutics Unveils Enchant AI to Predict Clinical Outcomes Using Preclinical Data

Iambic Therapeutics has announced the launch of Enchant, an AI platform designed to predict clinical outcomes from the earliest stages of drug discovery. Enchant is a multi-modal transformer model that …

Continue ›››

Stem Cell Transplant 'Black Box' Unveiled in 31-Year Study of Blood Cells

A pioneering study has provided the first detailed insight into the long-term behavior of stem cells following transplants, offering new hope for improving the procedure that has remained largely unexplained …

Continue ›››

Global Pharma R&D Investments Surpass $276 Billion Annually, Exceeding Previous Estimates

A recent study, titled Comprehensive Measurement of Biopharmaceutical R&D Investment, published in Nature Reviews Drug Discovery, reveals that global pharmaceutical R&D expenditures are significantly higher than previously reported. According to …

Continue ›››